Publications

• Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial.
  Nat Cancer Volume: 6 Page(s): 432 - 444
  03/01/2025 Authors: Bilen MA; Vo BT; Liu Y; Greenwald R; Davarpanah AH; McGuire D; Shiradkar R; Li L; Midya A; Nazha B
• Characteristics, Treatment, and Outcomes of Primary Urethral Cancer: A Multicenter Review Over Two Decades.
  Clin Genitourin Cancer Volume: 23 Page(s): 102276
  02/01/2025 Authors: Hopkins BD; Qian DC; Xu KM; McCook-Veal A; Switchenko J; Hartsell LM; Cimmino CB; Joshi SS; Narayan V; Master VA
• Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution Experience.
  J Immunother Precis Oncol Volume: 8 Page(s): 1 - 10
  02/01/2025 Authors: Zhuang TZ; Goyal S; Case KB; Olsen TA; Vemuru S; Yildirim A; Goswamy RV; Brown JT; Carthon BC; Kucuk O
• Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.
  Volume: 17 Page(s): 17588359251316243
  01/01/2025 Authors: Yildirim A; Wei M; Liu Y; Nazha B; Brown JT; Carthon BC; Choi Y; Suh L; Goswamy RV; McClintock GR
• PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.
  Cancer Volume: 130 Page(s): 3658 - 3670
  11/01/2024 Authors: Martini DJ; Case KB; Gratz D; Pellegrini K; Beagle E; Schneider T; Dababneh M; Nazha B; Brown JT; Joshi SS
• Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial.
  Res Sq
  08/08/2024 Authors: Bilen MA; Vo BT; Liu Y; Greenwald R; Davarpanah AH; McGuire D; Shiradkar R; Li L; Nazha B; Brown JT
• Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study
  Volume: 42
  06/01/2024 Authors: Nazha B; Brown JT; Liu Y; Kissick H; Carthon BC; Kucuk O; Harik LR; Narayan VM; Joshi SS; Bilen MA
• Association of immune-related adverse events, inflammatory biomarkers, and clinical outcomes in patients treated with ICIs for advanced renal cell carcinoma
  Volume: 42
  06/01/2024 Authors: Yildirim A; Wei M; Liu Y; Goswamy RV; Choi Y; Brown JT; Nazha B; Martini DJ; Hartman C; McClintock GR
• Clinical outcome differences based on gender in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs)
  Volume: 42
  06/01/2024 Authors: Choi Y; Goswamy RV; Wei M; Liu Y; Yildirim A; Brown JT; Nazha B; Martini DJ; Hartman C; McClintock GR
• Association of race with clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs)
  Volume: 42
  06/01/2024 Authors: Choi Y; Yildirim A; Wei M; Liu Y; Goswamy RV; Brown JT; Nazha B; Martini DJ; Hartman C; McClintock GR
• Association of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC)
  Volume: 42
  06/01/2024 Authors: Goswamy RV; Yildirim A; Wei M; Liu Y; Choi Y; Brown JT; Nazha B; Master VA; Martini DJ; Carthon BC
• Association of body mass index (BMI) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC)
  Volume: 42
  06/01/2024 Authors: Goswamy RV; Yildirim A; Choi Y; Wei M; Liu Y; Brown JT; Nazha B; Martini DJ; Hartman C; McClintock GR
• Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma
  Volume: 42
  06/01/2024 Authors: Brown JT; Nazha B; Liu Y; Lozada K; Smith JD; Hartman C; McClintock GR; Kucuk O; Carthon BC; Harvey RD
• Real world outcomes with cabazitaxel (cab) plus carboplatin (car) in metastatic castration-resistant prostate cancer (mCRPC)
  Volume: 42
  06/01/2024 Authors: Vemuru S; Goyal S; Liu Y; Zhuang T; Patel D; Kucuk O; Carthon BC; Nazha B; Bilen MA; Brown JT
• Baseline geriatric 8 (G8) screening tool to predict overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors.
  Volume: 42
  06/01/2024 Authors: Rhee CH; Goyal S; Liu Y; Martini DJ; Nazha B; Kucuk O; Carthon BC; Bilen MA; Brown JT
• Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
  Cancer Volume: 130 Page(s): 1642 - 1649
  05/01/2024 Authors: Miller EJ; Rose TL; Maughan BL; Milowsky MI; Bilen MA; Carthon BC; Gao X; Rapisuwon S; Zhao Q; Yu M
• Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study.
  Arch Pathol Lab Med Volume: 148 Page(s): 310 - 317
  03/01/2024 Authors: Bidot S; Yin J; Zhou P; Zhang L; Deeb KK; Smith G; Hill CE; Xiu J; Bilen MA; Case KB
• Interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.
  Volume: 42 Page(s): 609 - 609
  02/01/2024 Authors: Brown JT; Nazha B; Liu Y; Ranbhise S; Lozada K; Hartman C; McClintock GR; Kucuk O; Carthon BC; Harvey RD
• Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual.
  Front Health Serv Volume: 4 Page(s): 1254294
  01/01/2024 Authors: Hoin JA; Carthon BC; Brown SJ; Durham LM; Garrot LC; Ghamande SA; Pippas AW; Rivers BM; Snyder CT; Gabram-Mendola SGA
• Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
  Cancer Volume: 129 Page(s): 3884 - 3893
  12/15/2023 Authors: Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI
• Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
  Oncologist Volume: 28 Page(s): 1072 - 1078
  12/11/2023 Authors: Sanda GE; Shabto JM; Goyal S; Liu Y; Martini DJ; Nazha B; Brown JT; Yantorni LB; Anne Russler G; Caulfield S
• The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression.
  Cancers (Basel) Volume: 15
  12/06/2023 Authors: Hadadi A; Krause HB; Elliott A; Brown JT; Nazha B; Harik LR; Carthon BC; Miron B; Nabhan C; Barata PC
• Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.
  Clin Genitourin Cancer Volume: 21 Page(s): 546 - 554
  10/01/2023 Authors: Carthon BC; Kim SE; McDermott DF; Dutcher JP; Puligandla M; Manola J; Pins M; Carducci MA; Plimack ER; Appleman LJ
• Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study
  ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
  06/19/2023 Authors: Bidot S; Yin J; Zhou P; Zhang L; Deeb K; Smith GH; Hill C; Xiu J; Bilen M; Case K
• Molecular and immune analysis of adrenocortical carcinoma (ACC): Implications for immune checkpoint inhibition (ICI)
  Volume: 41
  06/01/2023 Authors: Nazha B; Gandhi N; Naqash AR; Hadfield MJ; Zhuang T; Brown JT; Carthon BC; Barata PC; Agarwal N; Soares HP
• Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
  Oncologist Volume: 28 Page(s): 239 - 245
  03/17/2023 Authors: Zhuang TZ; Ravindranathan D; Liu Y; Martini DJ; Brown JT; Nazha B; Russler G; Yantorni LB; Caulfield S; Carthon BC
• Exploration of immunosuppressive features of the tumor microenvironment within hepatic and non-hepatic tumors of urothelial origin.
  Volume: 41
  02/20/2023 Authors: Brown JT; Elliott A; Walker P; Xiu J; Nazha B; Stewart TF; Gulati S; Nandagopal L; Goldman J; Kucuk O
• Association of baseline inflammatory biomarkers with outcomes in penile squamous cell carcinoma (pSCC) treated with immune checkpoint inhibitors (ICI).
  Volume: 41
  02/20/2023 Authors: Zhuang T; Goyal S; Brown JT; Carthon BC; Kucuk O; McClintock GR; Yantorni LB; Bilen MA; Master VA; Nazha B
• The genomic landscape of urothelial carcinoma with high and low ERBB2/HER2 expression.
  Volume: 41
  02/20/2023 Authors: Hadadi A; Krause H; Elliott A; Farrell AP; Brown JT; Nazha B; Harik L; Carthon BC; Nabhan C; Barata PC
• Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.
  Volume: 41
  02/20/2023 Authors: Pachynski RK; Iannotti N; Laccetti AL; Carthon BC; Chi KN; Smith MR; Vogelzang NJ; Tu W; Kwan EM; Wyatt AW
• Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [68Ga]Ga DOTATATE PET-CT.
  Cancers (Basel) Volume: 14
  12/08/2022 Authors: Bilen MA; Akintayo A; Liu Y; Abiodun-Ojo O; Kucuk O; Carthon BC; Schuster DM; Parent EE
• Characteristics, Treatment and Outcomes of Patients with Primary Urethral Cancer: A Multi-Center Review over Two Decades
  Volume: 114 Page(s): E267 - E268
  11/01/2022 Authors: Qian DC; Xu KM; Hartsell LM; Cimmino CB; Joshi SS; Filson CP; Master V; Sanda MG; Nazha B; Carthon B
• IMPACT OF IMMUNOTHERAPY TIME-OF-DAY INFUSION ON OVERALL SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
  Volume: 10 Page(s): A886 - A886
  11/01/2022 Authors: Patel J; Draper A; Woo Y; Dhabaan L; Patel P; Jani A; Carthon B; Master V; Kissick H; Bilen M
• REAL-WORLD OUTCOMES IN PATIENTS WITH PENILE SQUAMOUS CELL CARCINOMA (PSCC) RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICI)
  Volume: 10 Page(s): A498 - A499
  11/01/2022 Authors: Zhuang T; Goyal S; Brown J; Carthon B; Kucuk O; McClintock G; Yantorni L; Bilen M; Master V; Nazha B
• A phase I study of palbociclib in combination with cisplatin or carboplatin in advanced solid malignancies
  Volume: 33 Page(s): S755 - S755
  09/01/2022 Authors: Alese OB; Bilen MA; Hitron E; Lewis C; Collins HH; Scott S; Carthon B; Cao Y; Switchenko JM; Harvey RD
• To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence.
  JAMA Oncol Volume: 8 Page(s): 1137 - 1138
  08/01/2022 Authors: Halabi S; Carthon BC; Kelly WK
• Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.
  J Immunother Precis Oncol Volume: 5 Page(s): 52 - 57
  08/01/2022 Authors: Martini DJ; Olsen TA; Goyal S; Liu Y; Evans ST; Hitron EE; Russler GA; Yantorni L; Caulfield S; Brown JT
• Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood.
  J Immunother Cancer Volume: 10
  07/01/2022 Authors: Carlisle JW; Jansen CS; Cardenas MA; Sobierajska E; Reyes AM; Greenwald R; Del Balzo L; Prokhnevska N; Kucuk O; Carthon BC
• Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.
  Cancers (Basel) Volume: 14
  06/10/2022 Authors: Zhuang TZ; Case K; Olsen TA; Brown JT; Carthon BC; Kucuk O; Goldman J; Harris W; Bilen MA; Nazha B
• Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
  Oncologist Volume: 27 Page(s): 462 - 468
  06/08/2022 Authors: Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA
• Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer.
  Urol Oncol Volume: 40 Page(s): 271.e9 - 271.e18
  06/01/2022 Authors: Hadadi A; Smith KE; Wan L; Brown JR; Russler G; Yantorni L; Caulfield S; Lafollette J; Moore M; Kucuk O
• Using real-world data to assess variations in cost and healthcare utilization for patients diagnosed with bladder cancer.
  Volume: 40 Page(s): E18815 - E18815
  06/01/2022 Authors: Boehmer L; Khaki AR; Carthon BC; Davis NB; Washington SL; Goltz HH; Lucas L; Mangir C
• Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
  Clin Cancer Res Volume: 28 Page(s): 1540 - 1548
  04/14/2022 Authors: Meric-Bernstam F; Tannir NM; Iliopoulos O; Lee RJ; Telli ML; Fan AC; DeMichele A; Haas NB; Patel MR; Harding JJ
• Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
  Cancer Volume: 128 Page(s): 966 - 974
  03/01/2022 Authors: Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Rezazadeh Kalebasty A
• Expression of Nectin-4 and PD-L1 in bladder cancer with variant histology.
  Volume: 40
  02/20/2022 Authors: Case K; Martini DJ; Dababneh M; Nazha B; Brown JT; Joshi SS; Narayan VM; Ogan K; Master VA; Carthon BC
• Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI).
  Volume: 40
  02/20/2022 Authors: Sanda GE; Shabto JM; Goyal S; Liu Y; Martini DJ; Nazha B; Brown JT; Yantorni LB; Russler G; Caulfield S
• Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.
  Volume: 40
  02/20/2022 Authors: Bilen MA; Liu Y; Nazha B; Brown JT; Osunkoya AO; Williams S; Session W; Yantorni LB; Russler G; Caulfield S
• Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers.
  Volume: 40
  02/20/2022 Authors: Nazha B; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Korn WM; Barata PC; Heath EI; Ryan CJ
• A Contemporary Clinicopathologic Analysis of Primary Urothelial Carcinoma of the Urethra Without Concurrent Renal Pelvic, Ureteral, or Bladder Carcinoma.
  Int J Surg Pathol Volume: 30 Page(s): 15 - 22
  02/01/2022 Authors: Chen F; Joshi S; Carthon BC; Osunkoya AO
• Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
  Clin Genitourin Cancer Volume: 20 Page(s): 53 - 59
  02/01/2022 Authors: Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S
• Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
  J Immunother Cancer Volume: 10
  01/01/2022 Authors: Zucali PA; Lin C-C; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su W-C; Massard C; Saleh M
• Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy.
  Front Endocrinol (Lausanne) Volume: 13 Page(s): 779915
  01/01/2022 Authors: Olsen TA; Zhuang TZ; Caulfield S; Martini DJ; Brown JT; Carthon BC; Kucuk O; Harris W; Bilen MA; Nazha B
• Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah's witness: A case report.
  Front Oncol Volume: 12 Page(s): 949400
  01/01/2022 Authors: Zhuang TZ; Harik L; Force S; Hadadi A; Bilen MA; Brown JT; Carthon BC; Goldman J; Kucuk O; Master VA
• Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
  Oncologist Volume: 26 Page(s): 1017 - 1025
  12/01/2021 Authors: Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L
• Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
  Oncologist Volume: 26 Page(s): 956 - 964
  11/01/2021 Authors: Smith KER; Brown JT; Wan L; Liu Y; Russler G; Yantorni L; Caulfield S; Lafollette J; Moore M; Kucuk O
• Primary urothelial carcinoma of the ureter without concurrent renal pelvic or bladder carcinoma: A contemporary clinicopathologic analysis.
  Volume: 226 Page(s): 153584
  10/01/2021 Authors: Gutierrez CM; Carthon BC; Joshi S; Osunkoya AO
• Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
  Oncologist Volume: 26 Page(s): e1742 - e1750
  10/01/2021 Authors: Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA
• Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database.
  Clin Genitourin Cancer Volume: 19 Page(s): e193 - e199
  08/01/2021 Authors: Xu KM; Liu Y; Gillespie TW; Osunkoya AO; Carthon B; Bilen MA; Filson CP; Ogan K; Patel PR; Shelton JW
• Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment.
  Oncologist Volume: 26 Page(s): 537 - 548
  07/01/2021 Authors: Carthon B; Sibold HC; Blee S; D Pentz R
• Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study.
  Volume: 81
  07/01/2021 Authors: Lin C-C; Zucali P; Carthon B; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su W-C; Massard C; Saleh M
• Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
  J Immunother Cancer Volume: 9
  07/01/2021 Authors: Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS
• 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
  Lancet Volume: 397 Page(s): 1895 - 1904
  05/22/2021 Authors: Jani AB; Schreibmann E; Goyal S; Halkar R; Hershatter B; Rossi PJ; Shelton JW; Patel PR; Xu KM; Goodman M
• Circulating tumor DNA (ctDNA) in patients with advanced adrenocortical carcinoma.
  Volume: 39
  05/20/2021 Authors: Nazha B; Dada HI; Drusbosky L; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Master VA; Bilen MA
• Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
  Volume: 39
  05/20/2021 Authors: Hamid O; Liu SV; Boccia RV; Call JA; Wise-Draper TM; Alistar AT; Powderly JD; Carthon BC; Vaishampayan UN; Olszanski AJ
• Association of basophil to lymphocyte ratio (BLR) with clinical outcomes in metastatic hormone sensitive prostate cancer.
  Volume: 39
  05/20/2021 Authors: Smith KER; Wan L; Liu Y; Brown JT; Russler G; Yantorni LB; Caulfield S; Carthon BC; Kucuk O; Nazha B
• Clinical outcomes in metastatic renal cell carcinoma (mRCC) treated with combination of nivolumab and cabozantinib (nivo-cabo) in the salvage setting.
  Volume: 39
  05/20/2021 Authors: Ravindranathan D; Liu Y; Martini DJ; Nazha B; Brown JT; Russler G; Yantorni LB; Caulfield S; Master VA; Carthon BC
• Baseline neutrophil-to-eosinophil ratio (NER) and its association with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).
  Volume: 39
  05/20/2021 Authors: Ravindranathan D; Liu Y; Martini DJ; Brown JT; Nazha B; Russler G; Yantorni LB; Caulfield S; Carthon BC; Kucuk O
• Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI).
  Volume: 39
  05/20/2021 Authors: Brown JT; Liu Y; Martini DJ; Shabto JM; Russler G; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K
• Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.
  Volume: 39
  05/20/2021 Authors: Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Kalebasty AR
• Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
  Oncologist Volume: 26 Page(s): 397 - 405
  05/01/2021 Authors: Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS
• Surgical Pathology Findings in Patients Who Have Undergone Radical Cystectomy/Cystoprostatectomy With Extended Versus Standard Lymph Node Dissection for Urothelial Carcinoma of the Bladder: A Contemporary Analysis.
  Int J Surg Pathol Volume: 29 Page(s): 150 - 154
  04/01/2021 Authors: Kagan J; Alemozaffar M; Carthon B; Osunkoya AO
• Primary Urothelial Carcinoma of the Urethra Without Concurrent Renal Pelvic, Ureteral or Bladder Carcinoma: A Contemporary Clinicopathologic Analysis
  Volume: 101 Page(s): 545 - 545
  03/01/2021 Authors: Chen F; Joshi S; Carthon B; Osunkoya AO
• Primary Urothelial Carcinoma of the Urethra Without Concurrent Renal Pelvic, Ureteral or Bladder Carcinoma: A Contemporary Clinicopathologic Analysis
  Volume: 34 Page(s): 545 - 545
  03/01/2021 Authors: Chen F; Joshi S; Carthon B; Osunkoya AO
• Primary Urothelial Carcinoma of the Ureter without Concomitant Renal Pelvic or Bladder Carcinoma: A Contemporary Clinicopathologic Analysis
  Volume: 34 Page(s): 561 - 561
  03/01/2021 Authors: Gutierrez C; Carthon B; Joshi S; Osunkoya AO
• Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal?
  Am Soc Clin Oncol Educ Book Volume: 41 Page(s): 1 - 12
  03/01/2021 Authors: Cackowski FC; Mahal B; Heath EI; Carthon B
• Primary Urothelial Carcinoma of the Ureter without Concomitant Renal Pelvic or Bladder Carcinoma: A Contemporary Clinicopathologic Analysis
  Volume: 101 Page(s): 561 - 561
  03/01/2021 Authors: Gutierrez C; Carthon B; Joshi S; Osunkoya AO
• Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).
  Volume: 39
  02/20/2021 Authors: Kucuk O; Smith C; Plasse T; Ogretmen B; Mehrotra S; Gourdin TS; Bilen MA; Carthon BC; Nazha B; Goldman J
• Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the CheckMate 920 trial.
  Volume: 39
  02/20/2021 Authors: Hutson TE; Carthon BC; Yorio J; Babu S; McKean HA; Percent IJ; Tykodi SS; Harrison MR; Zhang J; Zoco J
• Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
  Volume: 28 Page(s): 100393
  01/01/2021 Authors: Martini DJ; Kline MR; Liu Y; Shabto JM; Carthon BC; Russler GA; Yantorni L; Hitron EE; Caulfield S; Goldman JM
• Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database.
  Clin Transl Radiat Oncol Volume: 26 Page(s): 30 - 34
  01/01/2021 Authors: Janopaul-Naylor JR; Zhong J; Liu Y; Zhang C; Osunkoya AO; Joshi SS; Bilen MA; Carthon B; Kucuk O; Hartsell LM
• Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade.
  Front Oncol Volume: 11 Page(s): 701345
  01/01/2021 Authors: Olsen TA; Martini DJ; Goyal S; Liu Y; Evans ST; Magod B; Brown JT; Yantorni L; Russler GA; Caulfield S
• Exploratory study of 18F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer.
  Am J Nucl Med Mol Imaging Volume: 11 Page(s): 218 - 229
  01/01/2021 Authors: Akintayo AA; Bilen MA; Abiodun-Ojo OA; Kucuk O; Carthon B; Chen Z; Jani AB; Parent EE; Schuster DM
• Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors.
  Front Oncol Volume: 11 Page(s): 707050
  01/01/2021 Authors: Martini DJ; Olsen TA; Goyal S; Liu Y; Evans ST; Magod B; Brown JT; Yantorni L; Russler GA; Caulfield S
• Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer.
  Volume: 108 Page(s): 1397
  12/01/2020 Authors: Jani A; Schreibmann E; Goyal S; Raghuveer H; Hershatter B; Rossi PJ; Shelton JW; Patel PR; Xu KM; Goodman M
• Bladder Preserving Chemoradiotherapy Compared To Surgery For Variants Of Urothelial Carcinoma And Tumors With Divergent Differentiation: An Analysis Of The National Cancer Database
  Volume: 108 Page(s): E887 - E888
  11/01/2020 Authors: Janopaul-Naylor J; Zhong J; Liu Y; Zhang C; Osunkoya AO; Joshi SS; Bilen MA; Carthon B; Kucuk O; Hartsell LM
• EFFICACY OF SEQUENTIAL IMMUNE CHECKPOINT INHIBITION (ICI) IN PATIENTS WITH GENITOURINARY MALIGNANCIES
  Volume: 8 Page(s): A154 - A155
  11/01/2020 Authors: Evans S; Martini D; Magod B; Olsen T; Brown J; Yantorni L; Ravindranathan D; Russler G; Caulfield S; Goldman J
• BODY COMPOSITION AS A PREDICTIVE AND PROGNOSTIC BIOMARKER IN ADVANCED UROTHELIAL CARCINOMA (UC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
  Volume: 8 Page(s): A27 - A29
  11/01/2020 Authors: Martini D; Shabto J; Goyal S; Liu Y; Olsen TA; Evans S; Magod B; Ravindranathan D; Brown J; Yantorni L
• RACIAL DIFFERENCES IN OUTCOMES FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS MANAGED ON IMMUNE-CHECKPOINT INHIBITOR (ICI) THERAPY
  Volume: 8 Page(s): A133 - A133
  11/01/2020 Authors: Olsen TA; Martini D; Goyal S; Liu Y; Evans S; Magod B; Brown J; Yantorni L; Russler G; Caulfield S
• BODY COMPOSITION MAY BE PROGNOSTIC AND PREDICTIVE OF CLINICAL OUTCOMES IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
  Volume: 8 Page(s): A26 - A27
  11/01/2020 Authors: Martini D; Olsen TA; Goyal S; Liu Y; Evans S; Magod B; Brown J; Yantorni L; Russler G; Caulfield S
• IMMUNE-RELATED ADVERSE EVENTS (IRAES) MAY INDICATE A FAVORABLE PROGNOSIS IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
  Volume: 8 Page(s): A380 - A381
  11/01/2020 Authors: Martini D; Evans S; Goyal S; Liu Y; Olsen TA; Magod B; Brown J; Yantorni L; Russler G; Caulfield S
• PHASE 1/2 STUDY OF SUBCUTANEOUSLY ADMINISTERED ALKS 4230, A NOVEL ENGINEERED CYTOKINE, AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB, IN PATIENTS WITH ADVANCED SOLID TUMORS: ARTISTRY-2
  Volume: 8 Page(s): A227 - A227
  11/01/2020 Authors: Powderly J; Carthon B; Ernstoff M; Olszanski A; Wrangle J; Shields A; Piha-Paul S; Curtis K; Bidollari I; Du Y
• Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
  Br J Cancer Volume: 123 Page(s): 1228 - 1234
  10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA
• A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
  Clin Cancer Res Volume: 26 Page(s): 2497 - 2505
  06/01/2020 Authors: Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA
• Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors.
  Cancer Med Volume: 9 Page(s): 2752 - 2760
  04/01/2020 Authors: Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Brown J; Hitron EE; Russler GA; Caulfield S; Kissick H; Alemozaffar M
• Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
  Oncologist Volume: 25 Page(s): e528 - e535
  03/01/2020 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H
• Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
  Oncologist Volume: 25 Page(s): e484 - e491
  03/01/2020 Authors: Martini DJ; Liu Y; Shabto JM; Carthon BC; Hitron EE; Russler GA; Caulfield S; Kissick HT; Harris WB; Kucuk O
• Clinicopathologic Findings in Patients Who Have Undergone Radical Cystectomy/Cystoprostatectomy with Extended Versus Standard Lymph Node Dissection for Urothelial Carcinoma of the Bladder
  Volume: 100 Page(s): 907 - 907
  03/01/2020 Authors: Kagan J; Alemozaffar M; Carthon B; Osunkoya AO
• Clinicopathologic Findings in Patients Who Have Undergone Radical Cystectomy/Cystoprostatectomy with Extended Versus Standard Lymph Node Dissection for Urothelial Carcinoma of the Bladder
  Volume: 33 Page(s): 907 - 907
  03/01/2020 Authors: Kagan J; Alemozaffar M; Carthon B; Osunkoya AO
• Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI)
  Volume: 38
  02/20/2020 Authors: Brown JT; Liu Y; Martini DJ; Shabto JM; Hitron E; Russler G; Caulfield S; Yantorni LB; Joshi SS; Kissick H
• Association of baseline modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic urothelial cell carcinoma (mUCC) treated with immune checkpoint inhibitors (CPI)
  Volume: 38
  02/20/2020 Authors: Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron E; Russler G; Caulfield S; Yantorni LB; Joshi SS
• The role of 68Ga-DOTATATE for evaluation of patients with metastatic castration- resistant prostate cancer (mCRPC)
  Volume: 38
  02/20/2020 Authors: Bilen MA; Akintayo AA; Abiodun-Ojo OA; Kucuk O; Carthon BC; Schuster DM; Parent EE
• Adenosine receptor blockade with ciforadenant plus /- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC)
  Volume: 38
  02/20/2020 Authors: Harshman LC; Chu M; George S; Gordon B; Hughes M; Carthon BC; Fong L; Merchan JR; Kwei L; Hotson AN
• Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
  Cancer Volume: 126 Page(s): 575 - 582
  02/01/2020 Authors: Martini DJ; Kline MR; Liu Y; Shabto JM; Williams MA; Khan AI; Lewis C; Collins H; Akce M; Kissick HT
• Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study.
  Ther Adv Med Oncol Volume: 12 Page(s): 1758835920982859
  01/01/2020 Authors: Abousaud AI; Barbee MS; Davis CC; Caulfield SE; Wang Z; Boykin A; Carthon BC; Gogineni K
• Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report.
  Front Oncol Volume: 10 Page(s): 622134
  01/01/2020 Authors: Bilen MA; Jiang JF; Jansen CS; Brown JT; Harik LR; Sekhar A; Kissick H; Maithel SK; Kucuk O; Carthon B
• Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
  Oncologist
  12/05/2019 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H
• Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
  Oncologist
  12/05/2019 Authors: Martini DJ; Liu Y; Shabto JM; Carthon BC; Hitron EE; Russler GA; Caulfield S; Kissick HT; Harris WB; Kucuk O
• Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
  Invest New Drugs Volume: 37 Page(s): 1198 - 1206
  12/01/2019 Authors: Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL
• ARTISTRY-2: a phase 1/2 study of subcutaneously administrated ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
  Volume: 7
  11/06/2019 Authors: Powderly J; Carthon B; Ernstoff M; Olszanski A; Liu S; Curtis K; Du Y; Sun L; Putiri E; Wang Y
• Correlation of circulating CD8 T cell activation with response to immunotherapy in advanced renal cell carcinoma
  Volume: 7
  11/06/2019 Authors: Carlisle J; Jansen C; Reyes A; Prokhnevska N; Baumgarten D; Master V; Harvey RD; Carthon B; Kucuk O; Bilen M
• Small Cell Carcinoma of the Prostate: A Report of Outcomes of Localized Disease using the National Cancer Database
  Volume: 105 Page(s): E315 - E315
  09/01/2019 Authors: Xu KM; Liu Y; Gillespie T; Osunkoya AO; Carthon B; Bilen MA; Filson CP; Ogan K; Patel PR; Shelton JW
• Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
  BMC Cancer Volume: 19 Page(s): 857
  08/29/2019 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL
• Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
  Volume: 37
  05/20/2019 Authors: Martini DJ; Liu Y; Shabto JM; Carthon BC; Russler G; Hitron E; Caulfield S; Kissick H; Harris W; Kucuk O
• Safety and efficacy of nivolumab plus ipilimumab (NIVO plus IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.
  Volume: 37
  05/20/2019 Authors: Emamekhoo H; Olsen M; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Kalebasty AR
• Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).
  Volume: 37
  03/01/2019 Authors: Martini DJ; Shabto JM; Liu Y; Carthon BC; Speak A; Hitron E; Russler G; Caulfield S; Ogan K; Harris W
• Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
  Volume: 37
  03/01/2019 Authors: Martini DJ; Shabto JM; Liu Y; Carthon BC; Speak A; Hitron E; Russler G; Caulfield S; Ogan K; Harris W
• Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).
  Volume: 37
  03/01/2019 Authors: Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Kline MR; Hitron E; Russler G; Caulfield S; Kissick H; Alemozaffar M
• Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO).
  Volume: 37
  03/01/2019 Authors: Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Kline MR; Hitron E; Russler G; Caulfield S; Kissick H; Alemozaffar M
• Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO).
  Volume: 37
  03/01/2019 Authors: Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Kline MR; Hitron E; Russler G; Caulfield S; Kissick H; Alemozaffar M
• Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
  Volume: 37
  03/01/2019 Authors: Martini DJ; Shabto JM; Liu Y; Carthon BC; Speak A; Hitron E; Russler G; Caulfield S; Ogan K; Harris W
• Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
  Volume: 37
  03/01/2019 Authors: Martini DJ; Shabto JM; Liu Y; Carthon BC; Speak A; Hitron E; Russler G; Caulfield S; Ogan K; Harris W
• CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
  Volume: 37
  03/01/2019 Authors: Meric-Bernstam F; Lee RJ; Carthon BC; Iliopoulos O; Mier JW; Patel MR; Tannir NM; Owonikoko TK; Haas NB; Voss MH
• Sequential immunotherapy and association with clinical outcomes in advanced-stage cancer patients
  Volume: 7
  02/01/2019 Authors: Bilen M; Martini D; Liu Y; Lewis C; Collins H; Shabto J; Akce M; Kissick H; Carthon B; Shaib W
• Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.
  Volume: 42 Page(s): 36 - 41
  01/01/2019 Authors: Zhong J; Switchenko J; Jegadeesh NK; Cassidy RJ; Gillespie TW; Master V; Nieh P; Alemozaffar M; Kucuk O; Carthon B
• The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
  Cancer Volume: 125 Page(s): 127 - 134
  01/01/2019 Authors: Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL
• The addition of chemotherapy in the definitive management of high risk prostate cancer.
  Urol Oncol Volume: 36 Page(s): 475 - 487
  11/01/2018 Authors: Ferris MJ; Liu Y; Ao J; Zhong J; Abugideiri M; Gillespie TW; Carthon BC; Bilen MA; Kucuk O; Jani AB
• Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO).
  Volume: 29 Suppl 8 Page(s): viii42
  10/01/2018 Authors: Bilen MA; Martini DJ; Shabto JM; Liu Y; Khan AI; Williams MA; Lewis C; Collins HH; Kissick H; Carthon BC
• Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).
  Ann Oncol Volume: 29 Suppl 8 Page(s): viii433
  10/01/2018 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins HH; Akce M; Kissick H; Carthon BC; Shaib WL
• The Clinical Course of Patients With Prostate-Specific Antigen 100ng/ml: Insight Into a Potential Population for Targeted Prostate-Specific Antigen Screening.
  Urology Volume: 117 Page(s): 101 - 107
  07/01/2018 Authors: Leung AK; Hugar L; Patil D; Wong L; Carthon B; Carney KJ; Birdsong G; Moses KA; Master VA
• Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)
  Volume: 78
  07/01/2018 Authors: Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai R
• Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
  Clin Genitourin Cancer Volume: 16 Page(s): e563 - e575
  06/01/2018 Authors: Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA
• Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
  Volume: 36
  05/20/2018 Authors: Martini DJ; Liu Y; Lewis CM; Shabto JM; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai RN
• Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
  J Clin Oncol Volume: 36 Page(s): 1389 - 1395
  05/10/2018 Authors: Szmulewitz RZ; Peer CJ; Ibraheem A; Martinez E; Kozloff MF; Carthon B; Harvey RD; Fishkin P; Yong WP; Chiong E
• Divergent Histology and Aggressive Pathologic Features at Transurethral Resection of Bladder Tumor Correspond to Response Failure (as Compared to Success) with Neoadjuvant Chemotherapy: A Seven Year Retrospective Review of Cases Following Radical Cystectomy/Cystoprostatectomy for Urothelial Carcinoma
  Volume: 31 Page(s): 338 - 339
  03/01/2018 Authors: Ellis CL; Carthon BC; Osunkoya AO
• Divergent Histology and Aggressive Pathologic Features at Transurethral Resection of Bladder Tumor Correspond to Response Failure (as Compared to Success) with Neoadjuvant Chemotherapy: A Seven Year Retrospective Review of Cases Following Radical Cystectomy/Cystoprostatectomy for Urothelial Carcinoma
  Volume: 98 Page(s): 338 - 339
  03/01/2018 Authors: Ellis CL; Carthon BC; Osunkoya AO
• Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).
  Volume: 36
  02/20/2018 Authors: Tannir NM; Fan AC; Lee RJ; Carthon BC; Iliopoulos O; Mier JW; Patel MR; Meric-Bernstam F; DeMichele A; Voss MH
• Validation of a novel preoperative inflammatory score in localized, clear cell RCC.
  Volume: 36
  02/20/2018 Authors: Melnick KR; Patil DH; Khan AI; Kim FY; Bilen MA; Carthon BC; Kucuk O; Filson CP; Ogan K; Kissick HT
• Evaluation of serial measurements of C-reactive protein: Albumin ratio in patients with clear cell renal cell carcinoma.
  Volume: 36
  02/20/2018 Authors: Patil DH; Anastasiades EN; Torlak M; Lay A; Alemozaffar M; Pattaras J; Kucuk O; Carthon BC; Bilen MA; Ogan K
• Evaluation of preoperative C-reactive protein: Albumin ratio in patients with clear cell renal cell carcinoma.
  Volume: 36
  02/20/2018 Authors: Patil DH; Williams S; Torlak M; Alemozaffar M; Lay A; Pattaras J; Kucuk O; Carthon BC; Bilen MA; Ogan K
• Single center validation of neutrophil-to-lymphocyte ratio in localized and metastatic clear cell renal cell carcinoma.
  Volume: 36
  02/20/2018 Authors: Melnick KR; Patil DH; Khan AI; Kim FY; Torlak M; Bilen MA; Kucuk O; Carthon BC; Filson CP; Ogan K
• Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.
  Oncology Volume: 95 Page(s): 138 - 146
  01/01/2018 Authors: Owonikoko TK; Busari AK; Kim S; Chen Z; Akintayo A; Lewis C; Carthon BC; Alese OB; El-Rayes BF; Ramalingam SS
• A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma.
  Asian J Urol Volume: 4 Page(s): 230 - 238
  10/01/2017 Authors: Sekar RR; Patil D; Baum Y; Pearl J; Bausum A; Bilen MA; Kucuk O; Harris WB; Carthon BC; Alemozaffar M
• Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma.
  Tumour Biol Volume: 39 Page(s): 1010428317705514
  06/01/2017 Authors: Harris WB; Zhang C; Liu Y; Robertson DK; Akbashev MY; Lingerfelt BM; Kucuk O; Carthon BC; Gillespie TW; Osunkoya AO
• Single institution experience on papillary renal cell carcinoma PD-1/13D-L1 expression, pathological analysis, and outcomes after nephrectomy.
  Volume: 35
  05/20/2017 Authors: Carthon BC; Tabba M; Harris W; Kucuk O; Master VA; Ogan K; Osunkoya A; Ellis C
• Biomarker study of early death in patients with intermediate and favorable risk metastatic renal cell carcinoma.
  Volume: 35
  02/20/2017 Authors: Harris W; Zhang C; Liu Y; Kucuk O; Carthon BC; Master VA
• A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC).
  Volume: 35
  02/20/2017 Authors: Szmulewitz RZ; Ibraheem AF; Peer CJ; Figg WD; Carthon BC; Kozloff M
• Retrospective review of cytotoxic chemotherapy and anti-angiogenic combinations in renal cell carcinoma: A single institution experience.
  Volume: 35
  02/20/2017 Authors: Carthon BC; Tabba M; Ellis C; Harris W; Bilen MA; Canter D
• Prognostic Biomarkers of Systemic Inflammation in Patients with Metastatic Renal Cell Carcinoma
  Volume: 97 Page(s): 229A - 229A
  02/01/2017 Authors: Harris WB; Kucuk O; Carthon BC; Gillespie TW; Master VA; Osunkoya AO
• Prognostic Biomarkers of Systemic Inflammation in Patients with Metastatic Renal Cell Carcinoma
  Volume: 30 Page(s): 229A - 229A
  02/01/2017 Authors: Harris WB; Kucuk O; Carthon BC; Gillespie TW; Master VA; Osunkoya AO
• Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.
  Bone Marrow Transplant Volume: 52 Page(s): 132 - 134
  01/01/2017 Authors: DeFilipp Z; Rosand CB; Goldstein DA; Master VA; Carthon BC; Harris WB; Kucuk O; Al-Kadhimi Z; Cohen JB; Flowers CR
• Clinical Considerations and Challenges in Treating Patients With Oligometastatic Prostate Cancer.
  J Oncol Pract Volume: 13 Page(s): 19 - 20
  01/01/2017 Authors: Carthon BC
• Comparison of Outcomes in Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Chemoradiation.
  Int J Radiat Oncol Biol Phys Volume: 96 Page(s): S93 - S94
  10/01/2016 Authors: Zhong J; Switchenko J; Jegadeesh N; Gillespie TW; Master VA; Nieh P; Alemozaffar M; Kucuk O; Carthon B; Filson CP
• E2809. Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in prostate cancer (PC) patients (pts) with rising PSA at high risk of progression after local treatment (tx)
  Annals of Oncology Volume: 27 Page(s): vi249
  10/01/2016 Authors: Ferrari A; Chen YH; Hudes G; Carducci M; Antonarakis ES; Hahn NM; Ma H; Wong YN; Mayer T; Somer RA
• The STAMPEDE trial: paradigm-changing data through innovative trial design.
  Transl Cancer Res Volume: 5 Page(s): S485 - S490
  09/01/2016 Authors: Carthon BC; Antonarakis ES
• ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features.
  Volume: 34
  05/20/2016 Authors: Haas NB; Puligandla M; McDermott DF; Dutcher JP; Manola J; Pins M; Carducci MA; Vuky J; Carthon BC; Plimack ER
• High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Previously Treated Germ Cell Tumors: A Single-Center Experience
  Volume: 22 Page(s): S421 - S422
  03/01/2016 Authors: DeFilipp Z; Rosand CB; Goldstein DA; Master VA; Carthon BC; Harris WB; Kucuk O; Waller EK
• A novel preoperative inflammatory marker prognostic score in patients with clear cell and non-clear cell renal cell carcinoma.
  Volume: 34
  01/10/2016 Authors: Sekar RR; Patil D; Pearl J; Baum Y; Kucuk O; Harris WB; Carthon B; Alemozaffar M; Filson CP; Ogan K
• Nephrectomy status, race, and overall survival in patients with metastatic renal cell carcinoma.
  Volume: 34
  01/10/2016 Authors: Robertson DK; Zhang C; Liu Y; Gillespie TW; Kucuk O; Carthon BC; Master VA; Issa M; Petros J; Harris WB
• Dynamic correlation of serum C-reactive protein (CRP) levels with serum prostate-specific antigen (PSA) levels in patients with prostate cancer (PCa) on androgen deprivation therapy (ADT).
  Volume: 34
  01/10/2016 Authors: Kucuk O; Balci B; Liu Y; Zhang C; Yilmaz B; Atag E; Karaoglu A; Jani AB; Harris W; Carthon BC
• Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.
  Neuro Oncol Volume: 17 Page(s): 1312 - 1321
  10/01/2015 Authors: Patel KR; Lawson DH; Kudchadkar RR; Carthon BC; Oliver DE; Okwan-Duodu D; Ahmed R; Khan MK
• Kinetic risk assessment with biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma
  Volume: 75
  08/01/2015 Authors: Harris WB; Kucuk O; Carthon B; Liu Y; Pattaras J; Ogan K; Master V
• A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors
  Volume: 75
  08/01/2015 Authors: Owonikoko TK; Harvey RD; Lewis C; Chen Z; Kauh JS; Renfroe M; Deovic R; Sica GL; Carthon BC; Harris WB
• Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases.
  Can J Urol Volume: 22 Page(s): 7783 - 7787
  06/01/2015 Authors: Fatima N; Canter DJ; Carthon BC; Kucuk O; Master VA; Nieh PT; Ogan K; Osunkoya AO
• Characterization and survival of patients presenting with PSA values 100 or greater.
  Volume: 33
  05/20/2015 Authors: Leung AK; Hugar L; Patil D; Wong L; Carthon BC; Moses KA; Master VA
• Lycopene in the prevention of renal cell cancer in the TSC2 mutant Eker rat model.
  Volume: 572 Page(s): 36 - 39
  04/15/2015 Authors: Sahin K; Cross B; Sahin N; Ciccone K; Suleiman S; Osunkoya AO; Master V; Harris W; Carthon B; Mohammad R
• Lycopene in the prevention of renal cell cancer in the TSC2 mutant Eker rat model
  Archives of Biochemistry and Biophysics Volume: 572 Page(s): 36 - 39
  04/15/2015 Authors: Sahin K; Cross B; Sahin N; Ciccone K; Suleiman S; Osunkoya AO; Master V; Harris W; Carthon B; Mohammad R
• Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
  Invest New Drugs Volume: 33 Page(s): 397 - 408
  04/01/2015 Authors: Petrylak DP; Gandhi JG; Clark WR; Heath E; Lin J; Oh WK; Agus DB; Carthon B; Moran S; Kong N
• Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma.
  Int J Urol Volume: 22 Page(s): 264 - 270
  03/01/2015 Authors: Hsiao W; Herrel LA; Yu C; Kattan MW; Canter DJ; Carthon BC; Ogan K; Master VA
• Update on systemic therapy for advance prostate cancer.
  Curr Probl Cancer Volume: 39 Page(s): 52 - 62
  01/01/2015 Authors: Carthon B; Rossi PJ
• Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents
  CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Volume: 23
  11/01/2014 Authors: Owonikoko TK; Lewis C; Busari AK; Kim S; Chen Z; Lawson DH; Carthon BC; El-Rayes BF; Khuri FR; Kauh J
• Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis.
  BJU Int Volume: 113 Page(s): 871 - 877
  06/01/2014 Authors: Carthon BC; Ng CS; Pettaway CA; Pagliaro LC
• Therapeutic options for a rising PSA after radical prostatectomy.
  Can J Urol Volume: 20 Page(s): 6748 - 6755
  06/01/2013 Authors: Carthon BC; Marcus DM; Herrel LA; Jani AB; Rossi PJ; Canter DJ
• INITIAL EXPERIENCE ASSESSING PRE-OPERATIVE FRAILTY WITH PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CANCER
  Volume: 189 Page(s): E212 - E212
  04/01/2013 Authors: Ogan K; Taylor MD; Tai CG; Herrel LA; Cross B; Master VA; Carthon BC; Canter D
• NOMOGRAMS INCORPORATING SERUM C-REACTIVE PROTEIN (CRP) LEVELS EFFECTIVELY PREDICT MORTALITY AFTER NEPHRECTOMY.
  Volume: 189 Page(s): E306 - E307
  04/01/2013 Authors: Hsiao W; Herrel L; Yu C; Kattan M; Ogan K; Canter D; Pattaras J; Nieh P; Harris W; Carthon B
• A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results
  Volume: 31
  02/20/2013 Authors: Petrylak D; Gandhi JG; Clark WR; Heath EI; Lin J; Oh WK; Agus DB; Carthon BC; Moran S; Kong N
• A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results.
  J Clin Oncol Volume: 31 Page(s): 59
  02/20/2013 Authors: Gandhi JG; Clark WR; Heath EI; Lin J; Oh WK; Agus DB; Carthon BC; Moran S; Kong N; Suri A
• Salvage therapy for locally recurrent prostate cancer after radiation.
  Can J Urol Volume: 19 Page(s): 6534 - 6541
  12/01/2012 Authors: Marcus DM; Canter DJ; Jani AB; Dobbs RW; Schuster DM; Carthon BC; Rossi PJ
• PHASE 2 RESULTS FROM A PHASE 1/2 STUDY OF TAK-700 (ORTERONEL), AN ORAL, INVESTIGATIONAL, NONSTEROIDAL 17,20-LYASE INHIBITOR, WITH DOCETAXEL AND PREDNISONE (DP) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
  Volume: 23 Page(s): 302 - 303
  09/01/2012 Authors: Petrylak DP; Gandhi JG; Clark WR; Heath EI; Lin J; Oh WK; Agus DB; Carthon B; Moran S; Liu G
• Efficacy and tolerability of biweekly gemcitabine plus cisplatin (GEMCIS) or gemcitabine plus paclitaxel (GEMPAC) as neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
  Volume: 30
  05/20/2012 Authors: Karaoglu A; Nieh P; Canter D; Master VA; Carthon B; Harris W; Shelton J; Rossi PJ; Jani AB; Khan MK
• Caveolin-1 as a biomarker of Src family kinase/Abl inhibition in castrate-resistant prostate cancer
  JOURNAL OF CLINICAL ONCOLOGY Volume: 29
  03/01/2011 Authors: Carthon BC; Tahir S; Araujo JC; Wen S; Gallick GE; Logothetis C; Thompson TC
• Caveolin-1 as a biomarker of Src family kinase/Abl inhibition in castrate-resistant prostate cancer.
  J Clin Oncol Volume: 29 Page(s): 45
  03/01/2011 Authors: Carthon BC; Tahir S; Araujo JC; Wen S; Gallick GE; Logothetis C; Thompson TC
• Epidermal growth factor receptor (EGFR) targeted therapy in advanced metastatic squamous cell carcinoma (AMSCC) of the penis: Updates and molecular analyses.
  JOURNAL OF CLINICAL ONCOLOGY Volume: 28
  05/20/2010 Authors: Carthon BC; Pettaway CA; Pagliaro LC
• Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
  Clin Cancer Res Volume: 16 Page(s): 2861 - 2871
  05/15/2010 Authors: Carthon BC; Wolchok JD; Yuan J; Kamat A; Ng Tang DS; Sun J; Ku G; Troncoso P; Logothetis CJ; Allison JP
• Genetic replacement of cyclin D1 function in mouse development by cyclin D2.
  Mol Cell Biol Volume: 25 Page(s): 1081 - 1088
  02/01/2005 Authors: Carthon BC; Neumann CA; Das M; Pawlyk B; Li T; Geng Y; Sicinski P
• Cardiac myosin binding protein C mutations: A molecular basis for elderly-onset "sporadic" hypertrophic cardiomyopathy.
  CIRCULATION Volume: 98 Page(s): 245 - 245
  10/27/1998 Authors: Nimura H; Carthon BC; Maron BJ; McKenna WJ; Casey SA; O'Donoghue A; Seidman JG; Seidman CE
• Potential Impact of Sickle Hemoglobin Concentration on Survival Among Patients with Renal Medullary Carcinoma and Sickle Cell Trait
  
  Authors: Carden MA; Metts J; McCarty JM; Mitchell S; Carthon B; Siegel DA; Rapkin L; McLemore ML